AI-Driven Software Assists Radiologists in Reading Exams
|
By MedImaging International staff writers Posted on 01 Mar 2018 |
|
Image: The software engine named Transpara DBT is intended to assist radiologists in reading digital breast tomosynthesis and mammography exams (Photo courtesy of ScreenPoint Medical).
An Artificial Intelligence (AI)-driven decision support software engine, which assists radiologists in reading digital breast tomosynthesis (DBT) and mammography exams on breast-reading workstations, was launched at the European Congress of Radiology (ECR), Vienna, Austria, February 28 – March 4, 2018. The software engine named Transpara DBT was launched by ScreenPoint Medical (Nijmegen, Netherlands), which develops and markets image analysis technology and services for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in AI.
Transpara DBT utilizes breakthrough image analysis and deep learning technologies for providing information to significantly improve reading workflow for DBT on breast reading workstations. It allows the reader to automatically jump to a relevant DBT slice in both the CC and MLO 3D data, by simply clicking on a suspicious region in a synthetic mammogram. Transpara DBT marks the lesion in the relevant slices and provides quantitative decision support for individual soft tissue lesions and calcifications, thereby improving the radiologists’ reading accuracy and confidence in their assessment.
Additionally, Transpara DBT combines the analysis of soft tissue lesions and calcifications, if present, from all available views of an exam to compute a single score for the case on a scale of 1 to 10. This represents categories with increasing occurrence of cancer. The Transpara Score can be used by healthcare professionals and organizations to automatically identify exams that are highly likely to be normal and to help identify cases that need increased attention.
The software engine is multi-vendor and communicates via DICOM, allowing integration into PACS and mammography reading workstations. The Transpara algorithms use the full 3D information in DBT data and have been trained on very large databases, including thousands of examples of breast cancer and false positives.
“Transpara DBT was developed with the goal of improving the efficiency of reading tomosynthesis exams,” said Prof. Nico Karssemeijer, PhD, CEO of ScreenPoint Medical. “By providing interactive decision support to radiologists, we aim to help all readers achieve better performance and improve their workflow, representing a significant innovation in breast cancer screening.”
Related Links:
ScreenPoint Medical
Transpara DBT utilizes breakthrough image analysis and deep learning technologies for providing information to significantly improve reading workflow for DBT on breast reading workstations. It allows the reader to automatically jump to a relevant DBT slice in both the CC and MLO 3D data, by simply clicking on a suspicious region in a synthetic mammogram. Transpara DBT marks the lesion in the relevant slices and provides quantitative decision support for individual soft tissue lesions and calcifications, thereby improving the radiologists’ reading accuracy and confidence in their assessment.
Additionally, Transpara DBT combines the analysis of soft tissue lesions and calcifications, if present, from all available views of an exam to compute a single score for the case on a scale of 1 to 10. This represents categories with increasing occurrence of cancer. The Transpara Score can be used by healthcare professionals and organizations to automatically identify exams that are highly likely to be normal and to help identify cases that need increased attention.
The software engine is multi-vendor and communicates via DICOM, allowing integration into PACS and mammography reading workstations. The Transpara algorithms use the full 3D information in DBT data and have been trained on very large databases, including thousands of examples of breast cancer and false positives.
“Transpara DBT was developed with the goal of improving the efficiency of reading tomosynthesis exams,” said Prof. Nico Karssemeijer, PhD, CEO of ScreenPoint Medical. “By providing interactive decision support to radiologists, we aim to help all readers achieve better performance and improve their workflow, representing a significant innovation in breast cancer screening.”
Related Links:
ScreenPoint Medical
Ultrasound Table
Women’s Ultrasound EA Table
Digital Radiographic System
OMNERA 300M
Adjustable Mobile Barrier
M-458
Mobile X-Ray System
K4W
Latest Industry News News
- Nuclear Medicine Set for Continued Growth Driven by Demand for Precision Diagnostics
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
- Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions
- Polish Med-Tech Company BrainScan to Expand Extensively into Foreign Markets
Channels
Radiography
view channel
AI Boosts Breast Cancer Detection and Cuts Screening Workload
Breast cancer screening programs face rising demand and persistent workforce shortages, straining double-reading workflows and delaying care. Early detection is critical to reduce mortality and minimize... Read more
AI Tool Predicts Breast Cancer Risk Years Ahead Using Routine Mammograms
Breast cancer screening saves lives but still relies largely on uniform schedules despite wide differences in individual risk. This one-size-fits-all approach can miss cancers in higher-risk women while... Read more
MRI
view channel
MRI-Based AI Tool Supports Differentiation of Parkinsonian Syndromes
Clinicians often struggle to differentiate Parkinsonian syndromes at initial presentation, when symptom overlap can obscure disease trajectory and delay targeted care. Imaging markers derived from diffusion... Read more
MRI-Derived Biomarker Improves Risk Stratification in Glioblastoma
Glioblastoma is marked by rapid growth and diffuse infiltration that complicate prognosis and treatment planning. Clinicians need objective tools that capture both how these tumors expand and how they... Read more
Combined Imaging Approach Identifies Cause of Heart Attack without Coronary Blockage
Patients who present with myocardial infarction but show no obstructive coronary disease often leave without a definitive diagnosis. That uncertainty complicates in-hospital decision-making and post-discharge... Read more
Ultrasound
view channel
New Ultrasound AI Tool Supports Rapid Prenatal Assessment
Accurate gestational age estimation guides prenatal screening, detection of complications, and timely intervention. Access to ultrasound and trained sonographers is uneven, with nearly half of U.... Read more
New Consensus Standardizes Ultrasound-Based Fatty Liver Assessment
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rising along with obesity and diabetes, making accurate, scalable measurement of hepatic fat a clinical priority. Biopsy is invasive... Read more
Nuclear Medicine
view channel
PET Tracer Enables Noninvasive Measurement of Beta Cell Mass
Type 1 diabetes is an autoimmune disease in which the immune system destroys insulin-producing pancreatic beta cells. Loss of these cells destabilizes glucose control and drives complications.... Read more
New Imaging Tool Sheds Light on Tumor Fat Metabolism
Rapidly growing tumors reprogram metabolism to meet high energy demands. While many cancers preferentially consume glucose, lipid utilization by malignant cells is difficult to measure in living subjects.... Read more
Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies
Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more
General/Advanced Imaging
view channel
AI Tool Predicts Side Effects from Lung Cancer Treatment
Radiation therapy is a central treatment for lung cancer, but even carefully targeted radiation can affect surrounding healthy tissue. Patients may develop side effects such as lung inflammation, coughing,... Read more
AI Tool Offers Prognosis for Patients with Head and Neck Cancer
Oropharyngeal cancer is a form of head and neck cancer that can spread through lymph nodes, significantly affecting survival and treatment decisions. Current therapies often involve combinations of surgery,... Read more
Imaging IT
view channel
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
